Mark Raffeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark Raffeld has a total of 351 co-authors. Here are the top co-authors by number of shared publications:
- Liqiang Xi
National Institutes of Health, Bethesda, Maryland, United States
54 shared publications - Jaydira Del Rivero
Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD 20892, USA
39 shared publications - Anish Thomas
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
38 shared publications - Brett Schroeder
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
38 shared publications - Jung Kim
Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland
38 shared publications - Manoj Tyagi
Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland
38 shared publications
Latest Publications
- 13 April 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1808-1820
CNS tumor type prevalence according to age group: An analysis of 21 000 cases confirmed by methylation profiling, with a focus on adolescents and young adults
Background: Approximately 12 000 adolescents and young adults (ages 15-39, AYAs) are diagnosed with a primary central nervous system (CNS) tumor each year. DNA methylation profiling has transformed CNS tumor classification by refining diagnostic accuracy and identifying biologically distinct subtypes, but its application has not been systematically evaluated in the AYA population. In this study, we examined the spectrum of CNS tumor types across age groups, with a focus on the AYA population. Methods: We assembled a large dataset of CNS tumor samples with age annotations and methylation profiles matching with high confidence to a CNS tumor type using the NCI/Bethesda classifier. Prevalence of tumor type, methylation class and DNA copy number aberrations were compared across age strata (pediatric, AYA, and adult). Results: The cohort of 21 712 CNS tumors included 5351 tumors from AYAs (25%), which showed a mixed pattern, with tumors typical of childhood (eg, medulloblastoma) as well as those common in older adults (eg, glioblastoma). Several tumor types were specifically enriched in the AYA, including IDH-mutant astrocytoma, pleomorphic xanthoastrocytoma, posterior fossa group B ependymoma, and diffuse hemispheric glioma, H3 G34-mutant, among others. Distinct methylation subclasses of multiple tumor types were observed in the AYA, and patterns of genomic aberrations showed age-specific distributions. Conclusion: Large-scale methylation profiling revealed unique classification patterns of CNS tumors in AYAs, with specific tumor types, subclasses, and genomic alterations enriched in this population. These data may serve as a valuable reference resource for better understanding the spectrum of CNS tumors affecting AYA patients.
- 13 April 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1808-1820
CNS tumor type prevalence according to age group: An analysis of 21 000 cases confirmed by methylation profiling, with a focus on adolescents and young adults
Background: Approximately 12 000 adolescents and young adults (ages 15-39, AYAs) are diagnosed with a primary central nervous system (CNS) tumor each year. DNA methylation profiling has transformed CNS tumor classification by refining diagnostic accuracy and identifying biologically distinct subtypes, but its application has not been systematically evaluated in the AYA population. In this study, we examined the spectrum of CNS tumor types across age groups, with a focus on the AYA population. Methods: We assembled a large dataset of CNS tumor samples with age annotations and methylation profiles matching with high confidence to a CNS tumor type using the NCI/Bethesda classifier. Prevalence of tumor type, methylation class and DNA copy number aberrations were compared across age strata (pediatric, AYA, and adult). Results: The cohort of 21 712 CNS tumors included 5351 tumors from AYAs (25%), which showed a mixed pattern, with tumors typical of childhood (eg, medulloblastoma) as well as those common in older adults (eg, glioblastoma). Several tumor types were specifically enriched in the AYA, including IDH-mutant astrocytoma, pleomorphic xanthoastrocytoma, posterior fossa group B ependymoma, and diffuse hemispheric glioma, H3 G34-mutant, among others. Distinct methylation subclasses of multiple tumor types were observed in the AYA, and patterns of genomic aberrations showed age-specific distributions. Conclusion: Large-scale methylation profiling revealed unique classification patterns of CNS tumors in AYAs, with specific tumor types, subclasses, and genomic alterations enriched in this population. These data may serve as a valuable reference resource for better understanding the spectrum of CNS tumors affecting AYA patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Trial protocol dose limiting toxicity criteria
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Trial protocol dose limiting toxicity criteria
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Whole exome sequencing results
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Whole exome sequencing results
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Berzosertib pharmacodynamic assessment
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Berzosertib pharmacodynamic assessment
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500407
Immunotherapy Resistance in Lethal Prepubescent Spitz Melanoma With TERT Promoter Variant
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500407
Immunotherapy Resistance in Lethal Prepubescent Spitz Melanoma With TERT Promoter Variant
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Spatial Analysis of Hereditary Diffuse Gastric Cancer Reveals Indolent Phenotype of Signet Ring Cell Precursors
Marker genes used for annotating major cell types in single cell RNA sequencing analysis.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Spatial Analysis of Hereditary Diffuse Gastric Cancer Reveals Indolent Phenotype of Signet Ring Cell Precursors
Marker genes used for annotating major cell types in single cell RNA sequencing analysis.